Health Care · Biological Products, (No Diagnostic Substances) · OTC · CIK 1893219 · no price history on file
Price
Price series unavailable — No prices available for ABPWW in [1900-01-01, 2026-07-31]. This symbol may require bring-your-own-key (BYOK) data.
At a glance
Short interest is FINRA semi-monthly, settlement 2026-07-15.
Key fundamentals
ABPWW is not in the screener universe.
Trailing returns
No return windows available for ABPWW.
Risk
No risk analytics available for ABPWW.
Top institutional holders13F 2026-Q1
| Manager | Shares | Value | % sh out | QoQ |
|---|
| Diametric Capital, LP | 358,427 | $1,075 | — | +0.0% |
| MIZUHO SECURITIES USA LLC | 11,386 | $23 | — | new |
| BARCLAYS PLC | 8,333 | $17 | — | +0.0% |
| FLOW TRADERS U.S. LLC | 51,588 | $0 | — | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
Latest reported quarters
No reported quarters on file for ABPWW.
Basis & disclosures
- End-of-day only. Every price on this sheet is a stored CLOSE. Nothing here is live, intraday or delayed-real-time, and the sheet does not update after it is printed.
- Nothing is imputed. A figure that is not in the underlying filing or feed renders as “—”. We never fill a gap with an estimate, a peer median or a carried-forward value.
- Mixed as-of dates by design. Prices are at the last close; fundamentals are at the latest reported fiscal period; 13F ownership is at the latest filed quarter (45+ days in arrears); short interest is the latest FINRA settlement. Each block states its own basis above.
- Not investment advice. Model fair values, reverse-DCF grades and confidence labels are the output of published, disclosed methods on public filings — they are analysis, not a recommendation, a price target or a solicitation.
- Fundamentals and ownership derive from SEC EDGAR (and equivalent foreign registers); prices from a licensed end-of-day vendor, shown under a neutral source label. Full methodology at spzco.com/methodology.
